Welcome, everyone, to our interim report. Today, I, the CEO Martin Welschof, along with Stefan, will provide an update on the current and very compelling status of our company. I will jump right into the situation. So on this slide, we summarize the activities that we had. And I will start immediately with a news, as you probably also have seen from the report this morning. So we have additional positive data for our lead compound BI-1206 targeting FCγRIIB, especially for the subcutaneous formulation. And I will get back to more details there later. And this, I think, is a very nice example of our progress. So we had good data that we presented at ASCO where we saw four responders out of four patients. And now we have additional complete responses, partial responses, and stable disease, which is actually very good. And that was actually also the reason why we immediately pushed ahead with our subcutaneous formulation in our triplet combination. But I will come back to that later. And then the events that we had. So it was a very busy third quarter.
So we had additional positive efficacy data with our single agent arm of BI-1808, which is our lead compound targeting TNFR2. And that was from the Phase 2 program. And where we had a CTCL cohort, a very rare T-cell lymphoma, we saw three partial responses and one case of stable disease out of four heavily pretreated evaluable patients. And we feel this is something very interesting and exciting because it also gives us a couple of strategic options, which we might discuss later in our Q&A. Then we initiated our subcutaneous triplet combination for BI-1206, our premier program aimed at targeting FCγRIIB in conjunction with rituximab and acalabrutinib. So that has kicked off. As I mentioned earlier, we immediately started with a success. Our plan was originally to start with the intravenous formulation because at the time we decided on the triplet, the subcutaneous formulation was not ready, and we progressed quicker than planned. And that's why it is now with the Subcu formulation. We have received a notice of allowance for BI-1910, our second anti-TNF receptor two program. Um, and then also we established a new clinical trial, collaboration, and supply agreement with Merck MSD in order to evaluate BI-1607, our second anti FCγRIIB antibody in combination with KEYTRUDA as well as with ipilimumab. And I think this is also a very interesting combo. And I will come back to that later, in more detail. Then we presented two programs at ESMO. We gave a status update for BI-1910, and I will come back to that later. And then we also gave the status and could show promising anti-tumor activity in the ongoing Phase 1/2 trial with BT-001, which is our proprietary anti-CTLA-4 antibody in combination with the oncolytic virus vector from Transgene. So there, we could really show interesting anti-tumor activity in patients with solid tumors, actually quite promising, that had failed previous treatments. I will not dwell too much on this slide. It's just to remind you that we have always had a portfolio strategy. As you know, we have the first platform that has generated a number of programs. And we are currently focusing on three targets that you can see on the left-hand side of this slide. So TNFR2, where we probably have the most compelling and complete package at the moment. And TNF receptor two is actually a potential new checkpoint. So, this is very, very interesting.
And I'll come back to the two different compounds that we have in a minute. So this is BI-1808 and BI-1910. Then FCγRIIB, which is another interesting target in the tumor microenvironment. And there we have two programs, BI-1206 that we're currently developing in non-Hodgkin lymphoma as well as in solid tumors. And then BI-1607, that I just mentioned, that we're now going to develop in combination with pembrolizumab and ipilimumab. And then last but not least, CTLA-4. This is our proprietary antibody that we produce in a 50-50 joint venture with Transgene, where we combine this antibody with the oncolytic virus platform from Transgene, where we also just observed compelling data. Moving then into more details on the anti-TNFR2 program. So, two compounds. And just to remind everyone. Those two compounds were selected very diligently from several hundred. And those were the two that were very interesting preclinically and could potentially cure cancer in animals. And they have two distinct modes of action. And 1808 has been deleted. And that has already shown quite interesting data that we presented at ASCO. And then also around ESMO. So in the single-agent arm, I think I have to remind everybody. So those are obviously patients that are heavily pretreated. Sometimes they have undergone even 12 rounds of treatments with the standard of care. We have seen single-agent activity, which is very rare. Normally, you would only see that in combination. And 1808 is actually very strong and has very good activity. So we saw three partial responses. One patient achieved stable disease in the CTCL patient population that I outlined. And then, of course, in addition, we had those other responders in ovarian cancer, GIST, and also in lung cancer, which I think is very compelling to basically give you a quick overview of what we're doing, because we have a broad development program around BI-1808. So what I just mentioned pertains to the single agent activity. So there we have finished the dose escalation, which is part A. And now, in Phase 2a, for ovarian cancer and melanoma, then all tumor types, which primarily include GIST and lung cancer. And then there's CTCL, which I just mentioned on the previous slide. In parallel, we run the combination with pembrolizumab because we have seen in preclinical studies that these antibodies are not only interesting as a single agent, but also seem to have synergies with pembrolizumab in combination. And there we have finished the dose escalation and are now also moving into the dose expansion cohorts. As for the single agent compound, what is new here is that we will also start the combination with pembrolizumab and paclitaxel at some point. This is especially significant for ovarian cancer, which is a very hard nut to crack, and could be very interesting for patients. And then we will have other tumor types that we have not yet announced. So I think this will be a very interesting program.
And I'll come back later when we expect the further data on BI-1808. But I can mention already that we will have an update on the single agent by the end of the year. Then the second candidate that we have, 1910, had a trial in progress poster at ESMO, and there we could show a robust target occupancy. We conducted further exploration of the dose, safety, and tolerability. This trial is going very, very well. And, we will then, once we have finished the single agent dose escalation, go into several tumor types, including HCC. And the next step here actually, or the next milestone for this program, is the first Phase 1 single-agent data by the end of the year. So by the end of the year. Just to summarize it a little, we have further additional single agent data for 1808 as well as for 1910, then moving into our anti-FCγRIIB platform. Um, we have two candidates, 1206, which is our lead that we develop in a triplet for non-Hodgkin lymphoma, and then in combination with pembrolizumab for solid tumors. And then the second candidate is 1607. Starting with 1206 first. So there we had, and I mentioned it on my first slide. Very impressive clinical data. Additionally, we had one more for the subcutaneous administration. We had one additional complete response or one additional partial response, and then two more patients in stable disease, basically continuing the trend that we have seen previously. Aha. So now altogether we have two complete responses, three partial responses, and three stable diseases out of nine evaluable patients. So this is super, super compelling. And that's why we have started the triplet which is shown here on this slide with the Subcu. As I mentioned, the original plan was to use the intravenous formulation. But since we experienced rapid and robust development with the Subcu, we chose to proceed with the Subcu instead. And this is, of course, much more favorable from a product perspective because it's a difference of a couple of minutes with subcutaneous administration compared to one to two, or more, hours for IV application. So I think this also has direct product consequences. The triplet is running. I think it's a very competitive positioning because we expect to see a very strong overall response rate. What you would see also for, for instance, CAR-T as well as bispecifics, but a much, much better safety profile. So when you think about the US, for instance, the largest market for these kinds of products, the majority of cancer patients are treated at community hospitals and local hospitals, and they are overwhelmed dealing with toxicity, which is related to CAR-T or to some bispecifics. So for the majority, this would be the dream product, because then you don't have to wonder and you get the same, probably the same efficacy. You will see the first preliminary data set by the end of the year. And that, of course, will hopefully be telling. And that is of course also important for this program. So very, very excited about it. And it's running well. Then, moving on to BI-1206 in solid tumors and touching on the triplet, it's worth revisiting. So this runs in collaboration with AstraZeneca. They provide Acalabrutinib under a supply and collaboration agreement. And then, on the solid cancer side, we have the same arrangement in place with Merck, which I think is also a very interesting dynamic. The solid cancer combination also looks very interesting. So currently, we have 24 evaluable patients: we observed one complete response, one partial response, and seven patients in stable disease. These are obviously very heavily pretreated patients who do not respond anymore to this type of therapy. And the next step here will be when we disclose further Phase 1 data of this trial by mid-next year. But I will come back at the end to a summary of the milestones for next year, which are plentiful. Then, 1607, so this is actually quite interesting. 1607 is the second candidate targeting FcγRIIB. We have basically characterized this already, in combination with trastuzumab preclinically. We had two validations, one in combination with trastuzumab, the other in the triple combination with pembrolizumab and ipilimumab. And the trastuzumab combination. They presented that data from the dose escalation at the San Antonio Breast Cancer Symposium in December 2023. We were able to demonstrate that it was safe. We actually observed quite a number of cases of disease stabilization. So that was very interesting.
But the main reason why we did this was to demonstrate that our compound is safe before we attempt the triple combination, which we find more compelling. This has always been considered the holy grail by many treating oncologists, as combining pembrolizumab with ipilimumab has been challenging due to the toxicity profile of ipilimumab. Essentially, what we're attempting to accomplish is enabling this combination with our antibody BI-1607. So we will soon start patient recruitment for this triplet. Phase 1B to 2A study. With the first data set actually coming in during the second half of next year. It is also a very interesting program. Then, last but not least, the anti-CTLA-4. So this is a proprietary anti-CTLA-4 antibody that we discovered first. And that has been integrated into the oncolytic platform of Transgene. And we have now presented data at ESMO in combination with pembrolizumab. We could show that we can induce tumor regression in patients who failed previous anti-PD-L1 treatment, and one patient, actually with a heavily pretreated leiomyosarcoma, was able to modulate the tumor microenvironment, turning a cold tumor into a hot tumor, which I think is very interesting. So we have early signs, essentially of efficacy, with clinical responses observed in the BT-001 in combination with KEYTRUDA, affecting two out of six patients. This study is not yet fully complete. There will be further data collection toward the end of this year. So I think now we'll hand over to Stefan for the financial part.